In BARI-2D trial, the researchers have shown that insulin, and its secretagogues are more likely to cause an increased prevalence of albuminuria and coronary artery disease, compared to insulin-sensitizing drugs [22]. The gene discussed is INS; the disease is coronary artery disorder.